COMMUNIQUÉS West-GlobeNewswire
-
Foghorn Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026
05/06/2026 -
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05/06/2026 -
Seres Therapeutics Announces Two Transactions to Strengthen Balance Sheet, Reduce On-Going Lease Costs and Extend Projected Operating Cash Runway Well Into the First Quarter of 2027
05/06/2026 -
The Hemp Doctor Named Among the Best THC Drinks in 2026 by Beer Connoisseur
05/06/2026 -
New Health Economic Evidence Shows Health & Cost Benefits When Starting Dialysis at Home
05/06/2026 -
Fangzhou Showcases AI-Powered Chronic Disease Management Solution With Tencent Health at Tencent Cloud Conference
05/06/2026 -
Chiesi Global Rare Diseases Announces European Commission Approval of LOJUXTA® (lomitapide) ▼ Capsules for Paediatric Use in Homozygous Familial Hypercholesterolaemia (HoFH)
05/06/2026 -
Research Peptides: Koi Research Labs Expands Distribution Across USA & Canada
05/06/2026 -
Addex Convenes Annual General Meeting 2026
05/06/2026 -
Phase IIb Study Results of InnoCare’s Orelabrutinib in Patients with SLE Presented at 2026 EULAR
05/06/2026 -
Iron Age Nutrition Announces Launch of “Sour Apple Crush” Flavor in Total Hydrate Electrolyte Line
05/06/2026 -
Native Life Appoints FIFA Brand Designer Jody Ure to Lead Creative Strategy and Support National Expansion
05/06/2026 -
Laguna Treatment Center Warns of Concerning Increase in Patients Seeking Help for Kratom Addiction
05/06/2026 -
Aja Health and Wellness Inc. Announces Agreement for the Sale of Assets of GOeVisit Service
05/06/2026 -
Orange Plan Management Celebrates 4.9-Star Review Milestone, Reinforcing Its Role as a Leading NDIS Plan Manager in Australia
04/06/2026 -
NRx Pharmaceuticals, Inc. Announces Closing of $22.3 Million Public Offering of Common Stock and Including Exercise of the Underwriters’ Option
04/06/2026 -
DLH Announces Filing of New Shelf Registration Statement
04/06/2026 -
Cloudbreak Pharma Announces Final Patient Visit for 12-Month Efficacy Endpoint in Phase 3 Study of CBT-001 as a Potential Treatment for Pterygium
04/06/2026 -
Park Dental Partners Expands Presence in Rochester, Minn., with Addition of Zumbro View Dental
04/06/2026
Pages